What is Abzena?
Abzena operates as a leading partner research organization (PRO), providing comprehensive, integrated services that span discovery, development, and cGMP manufacturing for biologics and bioconjugates. The company offers a complete suite of solutions for early-stage discovery through mid-phase biotherapeutic and bioconjugation drug development and manufacturing. With facilities strategically located in the US and UK, Abzena is well-positioned to support global biopharmaceutical innovation.
How much funding has Abzena raised?
Abzena has raised a total of $113.6M across 5 funding rounds:
Stock Offering
$34.3M
Unspecified
$700K
Private Equity
$3.6M
Private Equity
$10M
Unspecified
$65M
Stock Issuance/Offering (2014): $34.3M, investors not publicly disclosed
Unspecified (2015): $700K, investors not publicly disclosed
Private Equity (2015): $3.6M, investors not publicly disclosed
Private Equity (2020): $10M featuring Biospring Partners
Unspecified (2022): $65M backed by Anderson & Stowe, Carson, and Welsh
Key Investors in Abzena
Welsh, Carson, Anderson & Stowe
Welsh, Carson, Anderson & Stowe is a prominent private equity firm known for its significant investments across various sectors, including healthcare and technology.
Biospring Partners
Biospring Partners is an investment firm that focuses on providing capital to companies within the life sciences and healthcare industries.
Undisclosed investor
An undisclosed investor participated in the recent funding round, contributing to Abzena's strategic growth initiatives.
What's next for Abzena?
The substantial enterprise-level funding and recent strategic investment indicate Abzena is poised for significant expansion and further integration of its service offerings. This capital will likely fuel advancements in their integrated discovery, development, and manufacturing capabilities for biologics and bioconjugates. The company's trajectory suggests a focus on scaling operations, enhancing technological platforms, and potentially pursuing strategic partnerships to broaden its market reach within the biopharmaceutical industry.
See full Abzena company page
